Literature DB >> 7189663

Immune complexes in thrombocytopenic patients: cause or effect?

R J Trent, R L Clancy, V Danis, A Basten.   

Abstract

Immune complexes (ICs) in the serum of 43 patients with chronic idiopathic thrombocytopenic purpura (ITP) were measured by the C1q deviation assay during the active and inactive phases of the disease. An inverse relationship between platelet count and levels of ICs was demonstrated in all but one patient. To test whether this phenomenon was specific for chronic ITP, ICs were assayed in sera from two groups of control patients with thrombocytopenia. Goup 1 had thrombocytopenia due to recognized immune mechanisms while group 2 had thrombocytopenia secondary to non-immune mechanisms. In both these groups the degree of thrombocytopenia proved to be inversely proportional to IC levels, which was similar to the pattern observed in chronic ITP. The specificity of the assay for detection of ICs was confirmed by demonstrating a positivity rate of 65% in sera of patients with systemic lupus erythematosus, a known IC disease. On analysis the ICs were shown to have molecular weights in excess of 500,000 daltons and contain variable immunoglobulin classes. The findings implicate ICs in immune destruction of platelets both in chronic ITP (as has been suggested previously) and also in thrombocytopenia secondary to known immune mechanisms. In addition the association of ICs with non-immune thrombocytopenias is consistent with the hypothesis that platelets play an important role in clearance of ICs from the circulation, thereby protecting the vascular endothelium from damage.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7189663     DOI: 10.1111/j.1365-2141.1980.tb08719.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Complement activation on platelets: implications for vascular inflammation and thrombosis.

Authors:  Ellinor I Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2010-06-01       Impact factor: 4.407

2.  Association of increased immune complexes, platelet IgG and serum IgG in chronic active hepatitis.

Authors:  S L Pfueller; B G Firkin; N Kerlero de Rosbo; A Riglar; I R Mackay
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

3.  Study of platelet-associated immunoglobulins of IgG, IgM, IgA, and IgE classes and platelet kinetics in 33 patients with idiopathic thrombocytopenic purpura.

Authors:  M R Movahed Shariat Panahi; S Le Blanc; O Schober; R Coldewey; H Deicher
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

4.  Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura.

Authors:  J Winiarski; G Holm
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

5.  Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  P Imbach; T W Jungi
Journal:  Blut       Date:  1983-03

Review 6.  An acquired-pseudo Bernard Soulier syndrome occurring with autoimmune chronic active hepatitis and anti-cardiolipin antibody.

Authors:  I L Beales
Journal:  Postgrad Med J       Date:  1994-04       Impact factor: 2.401

7.  Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells.

Authors:  C M Radder; H Beekhuizen; H H H Kanhai; A Brand
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  Platelet-associated IgG in hepatitis and cirrhosis.

Authors:  D Graber; D Giuliani; C M Leevy; B S Morse
Journal:  J Clin Immunol       Date:  1984-03       Impact factor: 8.317

9.  Idiopathic thrombocytopenia, initial illness and long term follow up.

Authors:  R W Walker; W Walker
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

10.  Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Authors:  Ellinor I B Peerschke; Biree Andemariam; Wei Yin; James B Bussel
Journal:  Br J Haematol       Date:  2009-11-19       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.